Cardiological features in idiopathic inflammatory myopathies

Journal of Cardiovascular Medicine

Volumn 11, Issue 12, 2010, Pages 906-911

  Bazzani, Chiara ^a   Cavazzana, Ilaria ^a   Ceribelli, Angela ^a   Vizzardi, Enrico ^b   Dei Cas, Livio ^b   Franceschini, Franco ^a  

^a Rheumatology Unit   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

heart; idiopathic inflammatory myopathies; polydermatomyositis

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN A; GADOLINIUM PENTETATE; LACTATE DEHYDROGENASE; METHOTREXATE;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; MUSCLE WEAKNESS; MYOSITIS; PATHOGENESIS; POLYMYOSITIS; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SCINTIGRAPHY; SEROLOGY; VASCULITIS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEART DISEASES; HUMANS; MYOSITIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 78649321986     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833cdca8     Document Type: Review

References (67)

1. Medsger TA, Oddis CV. Inflammatory muscle disease. Clinical features. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. Vol. 2. New York: Mosby; 1997. pp. 7.13.1-7.13.13.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis: Parts 1 and 2. N Engl J Med 1975; 292:344-347; 403-407.
3. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9:527-535.
4. Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol 2002; 14:653-657.
5. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
6. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22:668-674.
7. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005; 84:231-249.
8. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27:1150-1156.
9. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:1257-1266.
10. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis and therapy. Ann Int Med 1995; 122:715-723.
11. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20:857-880.
12. Vasquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996; 39:292-296.
13. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheum Rep 2008; 10:333-340.
14. Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H. Clinical utility of antisignal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology2008; 47:1539-1542.
15. Miller T, Al-Lozi MT, Lopote G, Pestronk A. Myopathywith antibodiestothe signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
16. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Antisignal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215.
17. Hengstman GJD, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, van Engelen BG. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential of the idiopathic inflammatory myopathies. J Neurol 2002; 249:69-75.
18. Hengstman GJD, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Antisignal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638.
19. Yamanishi Y, Maeda H, Katayama S, Ishioka S, Yamakido M. Sclerodermapolymyositis overlap syndrome associated with anti-Ku antibodies and rimmed vacuole formation. J Rheumatol1996; 23:1991-1994.
20. Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002; 29:1393-1397. (Pubitemid 34755602)
21. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148-159.
22. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies III: immunoelectron microscopy aspects of cell-mediated muscle fibre injury. Ann Neurol1986; 19:112-125.
23. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 31:329-334.
24. O'Hanlon TP, Miller FW. T cell-mediated immune mechanisms in myositis. Curr Opin Rheumatol1995; 7:503-509.
25. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, et al. T cell infiltrates in the muscles of patientswith dermatomyositisand polymyositis are dominated by CD28(null) T cells. J Immunol 2009; 183:4792-4799.
26. Wolf RE, Baethge BA. Interleukin1 alpha, interleukin 2 and soluble interleukin 2 receptors in polymyositis. Arthritis Rheum 1990; 33:1007-1014.
27. Mackiewicz Z, Hukkanen M, Povilenaite D, Sukura A, Fonseca JE, Virtanen I, Konttinen YT. Dual effects of caspase 1, interleukin 1 beta, tumor necrosis factor-alpha and nerve growth factor receptor in inflammatory myopathies. Clin Exp Rheumatol 2003; 21:41-48.
28. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factor alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 2000; 99:585-588.
29. Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G. Expression of tumor necrosis factor alpha in regenerating muscle fibers in inflammatory and noninflammatory myopathies. Acta Neuropathol 2003; 105:217-224.
30. Tateyama M, Nagano I, Yoshioka M, Chida K, Nakamura S, Itoyama Y. Expression of tumor necrosis factor-alpha in muscles in polymyositis. J Neurol Sci 1997; 146:45-51.
31. Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol1995; 59:185-194.
32. Shindoh C, Hida W, Ohkawara W, Yamauchi K, Ohno I, Takishima T, Shirato K. TNFalfa mRNA expression in diaphragm muscle after endotoxin administration. Am J Respir Crit Care Med 1995; 152:1690-1696.
33. De Rossi M, Bernasconi P, Baggi F, De Waal M, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol2000; 12:1329-1335.
34. Dhawan S, Singh S, Aggarwal BB. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: roleof the nucleartranscription factor NF-κB. Eur J Immunol 1997; 27:2172-2179.
35. MacKay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor alpha (TNFalfa)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993; 177:1277-1286.
36. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6:2391.
37. Lundberg IE.The physiologyofinflammatorymyopathies: an overview. Acta Physiol Scand 2001; 171:207-213.
38. Lundberg IE, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:865-874.
39. Buck M, Chojker M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibition of nitric oxide synthesis and antioxidants. EMBO J 1996; 15:1753-1765.
40. De Bleecker JL, Meire VI, Declercq W,Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromusc Disord 1999; 9:239-246.
41. Bronner IM, Hoogendijk JE, Veldman H, Ramkema M, van den Bergh Weerman MA, Rozemuller AJ, de Visser M. Tubuloreticular structures in different types of myositis: implications for pathogenesis. Ultrastruct Pathol 2008; 32:123-126.
42. Creus KK, De Paepe B, De Bleecker JL Idiopathic inflammatory myopathies and the classical NF-κB complex: current insights and implications for therapy. Autoimmun Rev 2009; 8:627-631.
43. Eloranta ML, Helmers SB, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007; 56:3112-3124.
44. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002; 41:22-26.
45. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-termsurvival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004; 83:35-42.
46. Torres C, Belmonte R, Carmona L, Gómez-Reino FJ, Galindo M, Ramos B, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity2006; 39:205-215.
47. Airio A, Kautiainen H, Hakala M. Prognosisand mortality in polymyositisand dermatomyositis patients. Clin Rheumatol 2006; 25:234.
48. Schwarz MI. Pulmonary and cardiac manifestations of polymyositis- dermatomyositis. J Thorac Imaging 1992; 7:46-54.
49. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/ dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15:168-178.
50. Gottdiener JS, Sherber HS, Hawley RJ, Engel WK. Cardiac manifestations in polymyositis. Am J Cardiol 1978; 41:1141-1149.
51. Gonzales-Lopez L, Gamez-Nava JI, Sanchez L, Rosas E, Suarez-Almazor M, Cardona-Muñoz C, Ramos-Remus C. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 1996; 14:373-379.
52. Denbow CE, Lie T, Trancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979; 22:1088-1092.
53. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109:1250-1258.
54. Taylor AJ, Wortham DC, Burge JR, Rogan KM. The heart in polymyositis: a prospective evaluation of 26 patients. Clin Cardiol1993; 16:802-808.
55. Coblyn JS, Weinblatt ME. Rheumatic diseases and the heart. In: Braunwald E, editor. Heart disease. A textbook of cardiovascular medicine. Philadelphia: WB Saunders; 1997. pp. 1779-1780.
56. Riemekasten G, Opitz C, Audring H, Barthelmes H, Meyer R, Hiepe F, Burmester GR. Beware of the heart, the multiple picture of cardiac involvement in myositis. Rheumatology 1999; 38:1153-1157.
57. Stern R, Godbold JH, Chess Q, Kagen LJ. ECG abnormalities in polymyositis. Arch Intern Med 1984; 144:2185-2189.
58. Lie JT. Cardiac manifestations in polymyositis/dermatomyositis: howto get to the heart of the matter. J Rheumatol 1995; 22:809-811.
59. Kuhl U, Lauer B, Souvatzoglu M, Vosberg H, Schultheiss HP. Antimyosin scintigraphy and immunohistologic analysis of endomyocardial biopsy in patients with clinically suspected myocarditis: evidence of myocardial cell damage and inflammation in the absence of histologic signs of myocarditis. JAm Coll Cardiol 1998; 32:1371-1376.
60. Erlacher P, Lercher A, Falkensammer J, Nassonov EL, Samsonov MI, Shtutman VZ, et al. Cardiac troponin and beta type myosin heavy chain concentrations in patients with polymyositis and dermatomyositis. Clin Chem Acta 2001; 306:27-33.
61. Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS. Cardiactroponin I is notexpressed infet al and healthyordiseased adult human skelet al muscle. Clin Chem 1995; 41:1710-1715.
62. Rama D, Margaritis I, Orsetti A, Marconnet P, Gros P, Larue C, et al. Troponin I immunoenzymometric assays for detection of muscle damage applied to monitoring a triathlon. Clin Chem 1996; 42:2033-2035.
63. Kiely PDW, Bruckner FE, Nisbet JA, Daghir A. Serum skelet al troponon I in inflammatory muscle disease: relation to creatine kinase, CKMB and cardiac troponin I. Ann Rheum Dis 2000; 59:750-751.
64. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97:1802-1809.
65. Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, Lundberg IE. Limited effects of high dose intravenous immunoglobulin (IVIg) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007; 66:1276-1283.
66. Touma Z, Arayssi T, Kibbi L, Marsi AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008; 75:334-337.
67. Afzal A, Higgins RS, Philbin EF. Hearttransplantfordilated cardiomyopathy associated with polymyositis. Heart 1999; 82:e4.